Sale!

Genryzon (Somatrogon) | 24mg

Original price was: $469.00.Current price is: $459.00.

Genryzon (Somatrogon) is a long-acting growth hormone analog designed to support lean muscle growth, fat loss, recovery, and longevity. With its once-weekly injection profile, it delivers consistent and sustained growth hormone activity without daily dosing.

Genryzon (Somatrogon) 24mg – Weekly Growth Hormone Optimization

Genryzon (Somatrogon) is a next-generation, long-acting recombinant human growth hormone (rhGH) analog fused with C-terminal peptide extensions to increase its half-life. Designed for once-weekly subcutaneous injection, Genryzon delivers steady and elevated GH and IGF-1 levels without the peaks and valleys of daily growth hormone therapy.

Each vial contains 24mg of lyophilized Genryzon (Somatrogon), ideal for advanced users seeking a long-acting, clinically proven growth hormone alternative for fat lossmuscle gainrecovery, and anti-aging benefits.

✨ Key Benefits

  • Stimulates IGF-1 Production: Promotes cellular growth, muscle repair, and regeneration
  • Accelerates Fat Loss: Enhances lipolysis and metabolic rate
  • Increases Lean Mass: Improves muscle density and nitrogen retention
  • Improves Sleep & Recovery: Optimizes healing during rest periods
  • Longevity Support: May improve skin, joints, cognition, and quality of life

⚙️ How Genryzon (Somatrogon) Works

Somatrogon is a bioengineered fusion protein combining recombinant human growth hormone (rhGH) with segments of human chorionic gonadotropin and albumin-binding domains. These extensions delay renal clearance and extend the peptide’s half-life to 6+ days — allowing for convenient once-weekly dosing while maintaining consistent GH activity. This improves IGF-1 regulation and reduces injection frequency compared to traditional GH protocols.

Product Specifications

Specification Details
Peptide Somatrogon (Genryzon)
Strength 24mg prefilled pen
Dosing Schedule Once per week, 0.2–0.6mg/kg (adjust based on goals)
Cycle Duration 12–24 weeks (long-term support)
Half-Life ~6 days
Storage Refrigerate after mixing
Reconstitution premixed

Advanced Use & Stacking – Growth Hormone (GH) Optimization

Synergistic Stacks for Maximum Benefits

  • With Ipamorelin or CJC-1295: Enhances pituitary function and promotes stronger GH pulsatility, supporting lean mass, recovery, and anti-aging effects.
  • With NAD+ or MOTS-c: Supports cellular repair, mitochondrial function, and energy production, complementing GH-mediated tissue regeneration.
  • With Metformin or Tirzepatide: Improves insulin sensitivity while boosting fat loss, optimizing metabolic balance during GH-focused protocols.

Why Choose Genryzon?

  • Convenient once-weekly injection schedule for consistent plasma GH levels
  • Stable GH levels without suppression or rebound effects
  • Clinically studied recombinant analog with a long safety record
  • Ideal for growth, fat loss, recovery, and longevity optimization
  • Can be safely stacked with compounds like Testosterone Cypionate, Testosterone Enanthate, Nandrolone Decanoate, or MK-677/Ibutamoren for enhanced anabolic and recovery benefits

Warnings & Considerations

  • Do not use during pregnancy or with active malignancy
  • Monitor IGF-1 levels during extended use
  • Consult a healthcare provider before starting any GH-based research protocol
  • Intended for research and laboratory purposes; not for human or veterinary use

Ideal For

  • Fitness enthusiasts seeking lean mass and improved recovery
  • Men and women exploring anti-aging or longevity therapies
  • Individuals with GH deficiency or age-related decline
  • Those wanting the benefits of GH without daily injections

This version naturally integrates your AASDirect links and targets keywords like:

  • “Growth hormone research chemical”
  • “Genryzon GH optimization”
  • “GH stack for fat loss and lean mass”
  • “Ipamorelin CJC-1295 stack”
  • “MK-677 GH synergy”

Reviews

There are no reviews yet.

Be the first to review “Genryzon (Somatrogon) | 24mg”

Your email address will not be published. Required fields are marked *